Greenwich LifeSciences disclosed that the 250 patients in the non‑HLA‑A*02 arm of its Phase III FLAMINGO‑01 trial have completed the full GLSI‑100 regimen and that preliminary analysis shows an annual breast‑cancer recurrence rate of less than 1 %—specifically 0.7 % over an average of 1.2 patient‑years—after the primary six‑dose series and subsequent boosters.
The data represent an approximately 83 % reduction compared with the 4 % annual recurrence rate observed in the KATHERINE study, which evaluated Kadcyla (ado‑trastuzumab emtansine). The reduction is statistically significant, indicating that GLSI‑100 may provide a markedly greater benefit than existing HER2‑targeted therapies that achieve roughly a 50 % reduction in recurrence.
GLSI‑100 is administered as a six‑dose primary immunization series followed by five booster injections every six months. The open‑label arm includes patients who are non‑HLA‑A02 positive; a separate randomized, double‑blind, placebo‑controlled component is enrolling HLA‑A02 positive patients. The trial has received FDA Fast Track designation, which could accelerate regulatory review if the data are confirmed.
The preliminary results are the first interim data from the fully enrolled open‑label arm of a Phase III study. If confirmed, the findings could position GLSI‑100 as a leading option for preventing breast‑cancer recurrence in HER2‑positive patients, potentially surpassing the efficacy of current standard therapies. The data may influence investor perception of the trial’s likelihood of meeting its primary endpoint and could affect future financing or partnership discussions.
Because the open‑label arm lacks a concurrent placebo comparator, the analysis relies on historical controls, and the data have not yet undergone full statistical review. The company has stated that the results are preliminary and subject to change as additional patient data are collected and analyzed.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.